LB Pharmaceuticals Inc
LBRXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeLB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The company carries a $1.59B market cap, placing it firmly in the small-cap category. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation.
Market Cap
$1.59B
Beta
—
P/E (TTM)
—
P/E (Fwd)
-9.81
EPS (TTM)
$-5.10
EPS (Fwd)
$-5.04
ROE
-50.0%
ROA
-30.0%
Cash
$327.8M
Total Debt
$5.2M
Free CF
-$53.9M
52W Change
185.2%
Annual Financials
Cash vs Debt
Where LBRX stands vs its 150-day and 200-day moving averages
As of the August 26, 2026 close, LBRX finished 61.64% above its 150-day moving average ($30.19) and 78.23% above its 200-day moving average ($27.38). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LBRX overbought or oversold?
At the August 26, 2026 close, LBRX's RSI(14) was 60.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $327.8M in cash and $5.2M in debt, LBRX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$53.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -50.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, LBRX has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing LBRX.